Over the past few years, a new class of medications has transformed the treatment of obesity. Drugs like Ozempic, Wegovy and Mounjaro work primarily by reducing appetite, helping people eat less and ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this ...

After years of fighting over compounded weight loss drugs, Hims & Hers and Novo Nordisk are teaming up to sell Ozempic and Wegovy — a shift that could raise costs for patients.

A new study suggests that a common menopause treatment may influence how effectively certain weight-loss medications work.

These brain areas are also linked to impulsivity and emotional control in people with ADHD. By reducing food cravings and constant thoughts about eating, GLP⁠-1s may help some people feel more focused ...

Share on Pinterest A new review of evidence found that intermittent fasting is no better than other dietary patterns for weight loss. yunxi xie/Getty Images Researchers report that intermittent ...

Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

This article was reviewed by Lynn Marie Morski, MD, JD. There’s not much research on B12 shots for weight loss. People with obesity tend to have lower vitamin B12 levels, but it’s unclear if B12 shots ...

Intermittent fasting appears to be no more effective for weight loss than doing nothing at all, according to a review of studies involving people who were overweight or had obesity. The diet has ...

A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from ...

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...